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Background. Aristolochic acid nephropathy (AAN) is a rap-
idly progressive interstitial nephropathy linked to the exposure
to aristolochic acid (AA) and characterized by extensive fibro-
sis and urothelial atypia. Although the fibrotic process has
been documented in extrarenal tissues, the involvement of the
peritoneum, as well as the efficacy of peritoneal dialysis in
AAN patients, remain uncertain.
Methods. The structure of the peritoneal membrane and the
expression of basic fibroblast growth factor (bFGF), collagen
type III, endothelial nitric oxide synthase (eNOS), and aqua-
porin-1 (AQP1) were investigated in peritoneal biopsies from
an index AAN patient, four other AAN patients, four regular
peritoneal dialysis patients, and two controls. Similar methods
were used to investigate a rabbit model of AAN after intraperi-
toneal exposure to high-dose AA. AA-DNA adducts were
screened by 32P-postlabeling analysis.
Results. The AAN patients had renal failure, renal fibrosis,
and urothelial atypia. The peritoneum of AAN patients had a
normal structure, lacked cellular atypia, and, in comparison
with regular peritoneal dialysis patients and controls, did not
show abnormal regulation of fibrotic and endothelial markers.
Furthermore, specific AA-DNA adducts were not identified
in the peritoneum of AAN patients. In contrast, AA-DNA
adducts were detected in peritoneal and kidney tissues of all
exposed rabbits, and one of them developed a malignant meso-
thelioma.
Conclusion. These data demonstrate the lack of fibrotic and
vascular alterations and the absence of cellular atypia in the
peritoneum from AAN patients. Thus, peritoneal dialysis
should not be discouraged in these patients. Nevertheless, stud-
ies in a rabbit model of high-dose AA exposure may suggest
a potential risk of peritoneal malignancy.
The so-called “Chinese herbs nephropathy” (CHN) is
a rapidly progressive nephropathy that was first de-
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scribed in 1992 in Belgian women who had followed a
particular weight-reducing regimen that included Chi-
nese herbs, Stefania tetrandra and Magnolia officinalis
[1]. The entity is characterized by extensive, hypocellular
interstitial fibrosis associated with renal tubular atrophy
and glomerulosclerosis, a decreasing corticomedullary
gradient of severity, and the presence of urothelial atypia
[2, 3], leading to the development of urothelial malig-
nancy in up to 50% of cases [4, 5]. To date, more than
100 patients with CHN have been identified in Belgium,
and similar cases have also been reported worldwide
[6, 7]. The exposure of CHN patients to aristolochic
acid (AA), a nephrotoxic and carcinogenic DNA binding
substance, has been documented by the demonstration
of AA-DNA adducts in renal biopsies [5, 8, 9]. The
observation of typical renal interstitial fibrosis and uro-
thelial malignancy in rabbits [10] and patients outside
the Belgian epidemic [6, 7] after exposure to AA conclu-
sively demonstrated the etiologic role of AA in the gene-
sis of the disease. Therefore, it has been proposed to
designate these cases as AAN rather than CHN, which
is less prejudicial for Chinese medicine [6].
Most patients with AAN progress to end-stage renal
failure requiring extrarenal depuration [11]. Hemodialy-
sis has been the usual treatment modality in these pa-
tients, and, to date, over half the Belgian AAN patients
have had renal transplantation [11]. In contrast with he-
modialysis, there has been little information regarding
the practicability of peritoneal dialysis in AAN patients.
A preliminary report suspected the presence of fibrosis
in the peritoneal membrane inherent to the intake of
aristolochic acid, which would advise against peritoneal
dialysis [12]. However, this hypothesis has not been con-
firmed and there is no information about the functional
and structural alterations of the peritoneal membrane
potentially induced by exposure to AA.
In this paper, we describe the characteristics of perito-
neal dialysis in an index patient with AAN and analyze
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Table 1. Clinical characteristics of aristochic acid nephropathy (AAN) patients
Case 1 (index case) Case 2 Case 3 Case 4 Case 5
Age years 67 57 55 61 46
Gender M/F F F F F F
Slimming regimen     
Chinese herbs ST, MO ST, MO ST, MO ST, MO a
Dialysis modality PD HD HD b HD
Pathology diagnosis of AANc TP TP TP TP Renal biopsy
AA-DNA adducts Kidney NA NA NA Kidney
Time of peritoneal biopsy CI KT NU KT NU
Methods of analysis IH, IB IH IH, IB IH IH
Abbreviations are: AAN, aristolochic acid nephropathy; ST, Stephania tetrandra; MO, Magnolia officinalis; AA, aristolochic acid; PD, peritoneal dialysis; HD,
hemodialysis; TP, nephro-ureterectomy specimen at time of renal transplantation; NA, not available; CI, PD catheter insertion; KT, kidney transplantation; NU,
nephro-ureterectomy; IH, immunohistochemistry; IB, immunoblotting.
a Chinese herbs bought in Shanghai [13]
b This patient underwent renal transplantation before dialysis initiation
c Histologic findings reported by Cosyns et al [2]
Table 2. Clinical and peritoneal equilibration test (PET) data of index case and regular peritoneal dialysis (PD) patients used for comparative studies
Index case PD 1 PD 2 PD 3 PD 4
Age years 63 52 42 28 33
Gender M/F F M F F F
Nephropathy AAN ADPKD IN Alport IN
Peritoneal biopsy CI KT KT CI (2nd) KT
Methods IH, IB IH, IB IH, IB IH, IB IH, IB
Time on PD before biopsy months / 36 10 2 11
D/P creatinine 0.51 0.7 0.7 0.74 0.58
D/D0 glucose 0.39 0.25 0.26 0.17 0.38
Sodium sieving % 10 6 8 7 7
Abbreviations are: AAN, aristolochic acid nephropathy; ADPKD, autosomal-dominant polykystic kidney disease; IN, interstitial nephritis; CI, catheter insertion;
KT, kidney transplantation; IH, immunohistology; IB, immunoblotting; D/P creatinine, dialysate over plasma ratio for creatinine measured at 4 hours of the dwell;
D/D0, final over initial glucose concentration in the dialysate; sodium sieving, difference between dialysate over plasma ratio for sodium at 60 minutes and initially
(time 0).
a peritoneal biopsy obtained at the time of catheter inser-
tion. Immunohistochemical and Western blot analyses
were used to compare the morphology and structure of
the peritoneum in this index case and four other AAN
patients versus four regular peritoneal dialysis patients
and two control subjects. These studies were completed
by investigations of peritoneal samples from rabbits that
developed AAN after exposure to high amounts of AA
for 21 months [10]. Our study demonstrates the lack of
abnormal fibrosis or vascular changes and the absence
of cellular atypia in the peritoneum of AAN patients.
However, a case of invasive mesothelioma was observed
in the high-dose AA exposure rabbit model.
METHODS
Case reports
The clinical characteristics of AAN patients are sum-
marized in Table 1.
Case 1 (index case). A 67-year-old woman with end-
stage renal failure due to interstitial nephropathy started
continuous ambulatory peritoneal dialysis in February
1999. She had previously taken slimming pills of un-
known origin. Peritoneal biopsy was obtained at the time
of catheter insertion. Four 1.5 L exchanges were per-
formed daily [daytime, 2  2.27% and 1  1.36% glu-
cose; nighttime, 1.36% glucose-based dialysates (Baxter
Healthcare, Lessines, Belgium)]. A peritoneal equilibra-
tion test (PET) using 3.86% glucose performed in March
1999 showed a low-average transport rate (Table 2). In
April 1999, the patient was switched to continuous cy-
cling peritoneal dialysis at her request. Daily ultrafiltra-
tion ranged from 800 mL to 1400 mL. A second PET,
performed in July 1999, was similar the previous evalua-
tion. In October 1999, she presented an acute peritonitis
due to Alcaligenes xylosoxidans. Despite antibiotherapy,
the peritonitis relapsed, requiring transfer to hemodialy-
sis. In January 2000, she underwent cadaver kidney trans-
plantation and homolateral nephro-ureterectomy was
performed. Pathologic examination revealed all the char-
acteristic features of CHN [3], including extensive hypo-
cellular interstitial fibrosis associated with tubular atro-
phy, decreasing corticomedullary gradient, and extensive
urothelial atypia. The patient later admitted that she had
ingested slimming pills containing the aristolochic acid
Stephania tetrandra and Magnolia officinalis [13].
Case 2. A 57-year-old woman who had taken slimming
pills containing Stephania tetrandra and Magnolia offici-
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nalis between January 1990 and July 1992 was referred
in September 1992 for evaluation of renal failure, severe
hypertension, and mild proteinuria. Renal function dete-
riorated and hemodialysis was required in February
1995. In September 1998, she underwent cadaver kidney
transplantation and a peritoneal biopsy was obtained.
The diagnosis of AAN was confirmed by the pathologic
examination of the nephro-ureterectomy specimen.
Case 3. A 55-year-old woman with renal failure due
to interstitial nephropathy was started on hemodialysis in
March 1999. In December 2000, she underwent cadaver
kidney transplantation together with nephro-ureterec-
tomy. Histology showed all pathognomonic features of
AAN. She had taken aristolochic acid, including Ste-
phania tetrandra and Magnolia officinalis. In order to
avoid the development of urothelial malignancy, contra-
lateral nephro-ureterectomy together with a peritoneal
biopsy was performed in April 2001.
Case 4. A 61-year-old woman had taken slimming pills
containing aristolochic acid (Stefania tetrandra and Mag-
nolia officinalis) from 1990 to 1992. In July 1992, she
developed renal failure associated with anemia and hy-
pertension. Renal function deteriorated progressively,
and she underwent cadaver kidney transplantation to-
gether with nephro-ureterectomy and peritoneal biopsy
in February 2000, before initiation of hemodialysis.
Pathologic examination of the kidney confirmed the di-
agnosis of AAN.
Case 5. A 46-year-old Chinese woman who had in-
gested for 6 months a traditional Chinese phytotherapy
bought in Shanghai developed a rapidly progressive re-
nal failure requiring hemodialysis in February 2000. Kid-
ney biopsy disclosed typical lesions of AAN. Moreover,
the presence of AA was demonstrated in the herbal
preparation, and AA-DNA adducts were identified in
the kidney tissue [14]. She underwent cadaver kidney
transplantation in June 2000 and contralateral nephro-
ureterectomy together with a peritoneal biopsy in April
2001.
Control patients
Para-umbilical biopsy samples of parietal peritoneum
were obtained from four regular peritoneal dialysis pa-
tients at the time of renal transplantation or catheter
insertion. A fifth sample was obtained at autopsy from
a patient who had been on peritoneal dialysis for 10
years and developed an extensive peritoneal fibrosis [15].
Peritoneal biopsies obtained from two nonuremic pa-
tients at the time of laparotomy for benign surgery were
used as healthy controls for immunoblotting analysis.
The Ethical Review Board of the Universite´ Catholique
de Louvain has approved the use of the human perito-
neum samples for these studies.
Peritoneal equilibration test (PET)
The PET was performed during a 4-hour dwell with
a 1.5 L 3.86% glucose solution. Dialysate samples (10
mL) were collected 0, 30, 60, 120, and 240 minutes after
intraperitoneal instillation of the dialysate. A blood sam-
ple was taken 120 minutes after onset of the test. Dialy-
sate/plasma (D/P) concentration ratio for creatinine at
4 hours and sodium after 60 minutes, and final over initial
glucose concentration ratio (D/D0) were determined as
previously described [16].
Tissue processing
Peritoneal biopsies were obtained from the para-
umbilical area of the parietal peritoneum at time of cath-
eter insertion or renal transplantation, and processed as
previously described [17]. Briefly, part of the samples
was fixed for 6 hours at 4C in 4% paraformaldehyde in
0.1 mol/L phosphate buffer, pH 7.4, rinsed in ice-cold
phosphate-buffered saline (PBS), and embedded in par-
affin. The other part of the samples was snap-frozen in
liquid nitrogen and used to prepare a total protein extract
as described [17, 18].
Histology and imunohistochemistry
Six micrometer thick sections were obtained from par-
affin blocks of all peritoneal biopsies and stained with
Masson’s trichrome and hematoxylin-eosin. Immuno-
staining for aquaporin-1 (AQP1) was performed for the
index AAN patient using an affinity-purified rabbit anti-
AQP1 (Chemicon International, Temecula, CA, USA)
as described previously [18].
Immunoblot analysis
Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and immunoblotting were per-
formed as described [17, 18]. The extracts were separated
by 7.5% or 12% SDS-PAGE and transferred to nitrocel-
lulose. After Ponceau Red (Sigma Chemical Co., St.
Louis, MO, USA) staining to check transfer efficiency,
membranes were incubated with the primary antibody
[mouse anti-endothelial nitric oxide synthase (eNOS),
1:5000 dilution (Transduction Laboratories, Lexington,
KY, USA); rabbit anti-aquaporin-1 (AQP1), 1:20,000
dilution (Chemicon International); goat anti-type III col-
lagen (collagen III), 1:500 dilution (Southern Biotech-
nology, Birmingham, AL, USA); rabbit anti-basic fibro-
blast growth factor (bFGF), 1:500 dilution (Santa Cruz
Biotechnology, Santa Cruz, CA, USA)] overnight at 4C.
The membranes were then washed, incubated for 1 hour
at room temperature with the appropriate peroxidase-
labeled antibody (1:5000 dilution), washed again, and
visualized with enhanced chemiluminescence. The speci-
ficity of the immunoreaction was determined by compari-
son with the signal observed with positive controls and
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incubation with nonimmune rabbit or mouse IgG (Vec-
tor Laboratories, Burlingame, CA, USA). All gels were
performed in duplicate. Densitometry analysis was per-
formed with a StudioStar Scanner (Agfa-Gevaert, Mors-
tel, Belgium), using the NIH-Image V1-57 software.
Rabbit model of high-dose exposure to AA
This model, performed on 15-week-old female New
Zealand white rabbits, has been described previously in
detail [10]. The 97% purity AA (Sigma Chemical Co.)
was initially dissolved in NaOH (5 g AA/L NaOH 25
mmol/L). Immediately prior to injection, this solution
was further diluted 50 times with saline and given by
intraperitoneal injection at the dose of 0.1 mg AA/kg, 5
days a week for 21 months (N  6). Four female control
rabbits received intraperitoneal saline for 21 months (N
4). Identical biopsy samples of parietal peritoneum were
obtained from all the animals at the time of sacrifice.
Additionally, kidney tissue samples from AA-exposed
rabbits (N  3) and control animals (N  3) were used
for DNA adduct analysis.
Identification of AA-DNA adducts
DNA isolation from kidney and peritoneum samples
was performed using the PuregeneR kit (Gentra, Minne-
apolis, MN, USA), with further purification by phenol-
extraction. 32P-Postlabeling analysis using nuclease P1
enrichment, chromatography on polyethyleneimine-cel-
lulose thin-layer plates (Machery and Nagel, Du¨ren, Ger-
many), autoradiography using a Packard Instant Imager
(Canberra Co., Dowers Grove, IL, USA), and quantita-
tion were performed as described previously [19]. Each
DNA sample was analyzed at least in duplicate and re-
sults were expressed as DNA adducts per 107 normal
nucleotides.
RESULTS
Peritoneal permeability test
A first PET was performed in the index AAN patient
1 month after peritoneal dialysis initiation (Table 2),
showing that the peritoneal membrane was in the low-
average permeability category as defined by Twardowski
et al [16]. The PET data of the four regular peritoneal
dialysis patients used for comparative studies are also
shown in Table 2. The patients (PD1 to PD3) were in the
high-average permeability category, whereas the PD4
patient had a low-average peritoneal membrane perme-
ability. It must be noted that the sodium sieving (i.e.,
the drop in the dialysate sodium concentration observed
after 60 minutes of a hypertonic dwell) was higher in the
index AAN patient than in the control regular peritoneal
dialysis patients.
Histology and immunohistochemistry of the
peritoneum exposed to AA
Representative hematoxylin-eosin stained sections of
the parietal peritoneum of the index AAN patient are
illustrated in Figure 1. The mesothelium was extensively
denuded, whereas the submesothelial tissue, including
peritoneal vessels, and the adjacent adipose tissue were
unremarkable (Fig. 1 A and B). In particular, there was
no evidence of hypocellular fibrosis areas or cellular
atypia in the biopsy. Immunostaining for the water chan-
nel AQP1, a marker of the capillary endothelium, showed
a normal density and the lack of vascular proliferation
(Fig. 1C). At higher magnification, the staining for AQP1
was normally restricted to the endothelial cells of perito-
neal capillaries and veinules (Fig. 1C, inset). Hematoxy-
lin-eosin–stained sections of the parietal peritoneum
(Fig. 1 D and E) and omentum (Fig. 1F) of the other
AAN patients studied showed similar, unremarkable
findings.
As shown on Figure 2, hematoxylin-eosin stained sec-
tions of the parietal peritoneum of rabbits exposed to a
high-dose AA did not show extensive fibrosis or vascular
proliferation. However, a focally invasive, papillary, and
in situ malignant mesothelioma was detected in one of
the six AA- treated rabbits (Fig. 2B). Gross examination
of the peritoneum of another AA-treated rabbit revealed
the presence of abundant gray-whitish nodules. Histo-
logic examination showed that these nodules correspond
to focal, nonspecific reactive inflammatory pseudo-tumors,
characterized by hyperplastic mesothelial cells covering
a myxoid submesothelial tissue containing abundant his-
tiocytes, mononuclear inflammatory cells, and few areas
of fibrosis. Of note, adjacent areas of parietal peritoneum
were normal (Fig. 2C).
Immunoblot analyses
Western blot and densitometry analyses were per-
formed to evaluate the expression of collagen III, the
growth factor bFGF, and the endothelial markers eNOS
and AQP1 in the peritoneum of the index AAN patient
versus regular peritoneal dialysis patients and normal
controls (Fig. 3). A long-term peritoneal dialysis patient
with peritoneal fibrosis was considered as a positive con-
trol for the expression of fibrosis markers [15]. As shown
on the representative immunoblot shown on Figure 3A,
the 140 kD band corresponding to collagen III was de-
tected with variable intensity in all human peritoneal
samples tested. The signal intensity in the index AAN
patient (lane 6) and an AAN patient on hemodialysis
(lane 5) was weak in comparison with regular peritoneal
dialysis patients (lanes 1 to 4) and normal controls (lanes
7 and 8). The 18 kD band corresponding to bFGF was
detected in a few peritoneum samples; it was absent in
the index AAN patient (lane 6), and weakly expressed
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Fig. 1. Structure of the peritoneum in aristolochic acid nephropathy (AAN) patients. (A and B ) Hematoxylin-eosin–stained sections of parietal
peritoneum of the index case. The mesothelium is extensively denuded, the submesothelial tissue, including peritoneal vessels, as well as the adjacent
adipose tissue are unremarkable. (C) Immunostaining for aquaporin-1 (AQP1) of parietal peritoneum of the index case is observed in the endothelium
lining, peritoneal capillaries, and small vessels, with no areas of vascular proliferation. The staining pattern is qualitatively normal, with labeling
of both plasma membranes of endothelial cells (inset). (D to F ) Hematoxylin-eosin stained sections of the parietal peritoneum of AAN case 2
(D), AAN case 5 (E), and omentum of AAN case 3 (F). The structure of the peritoneal membrane is normal in the three cases. Original
magnification (A, B, E, and F) 75; (C and D) 150; C, inset 300.
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Fig. 2. Structure of the peritoneum in aristolochic acid (AA)-treated
rabbits. (A ) Parietal peritoneum from a control rabbit showing meso-
thelial epithelial lining, submesothelial tissue, and abdominal skeletal
muscle. (B ) Parietal peritoneum from a rabbit injected intraperitoneally
0.1 mg AA/kg/day during 21 months. Mesothelial cells have an hyper-
plastic appearance on the left and develop a solid nest of infiltrating
neoplastic round cells with vesicular nuclei and prominent nucleoli on
the right. Hematoxylin-eosin (original magnification300). (C ) Parietal
peritoneum from a different rabbit injected intraperitoneally 0.1 mg
AA/kg/day during 21 months. Normal peritoneum (arrows). Focal de-
velopment of nodules (*) having a myxoid stromal appearance with
in the other AAN patient tested (lane 5) in comparison
with regular peritoneal dialysis patients (lanes 1 to 3).
The 135 kD band corresponding to eNOS was identified
with variable intensity in the peritoneum of all patients.
The expression of eNOS was clearly up-regulated in reg-
ular peritoneal dialysis patients (lanes 1 to 3), whereas
an intermediate signal was detected in the index case
(lane 6) and the peritoneal dialysis patient with low aver-
age PET (lane 4). It must be noted that, among perito-
neal dialysis patients, the expression of eNOS in the
peritoneum was particularly important in the high-aver-
age transporters (lanes 1 to 3). The 28 kD band corre-
sponding to AQP1 was identified in membrane extracts
from all human peritoneal samples tested. The expres-
sion of AQP1 was up-regulated in peritoneum extracts of
peritoneal dialysis patients with high-average transport
status (lanes 1 to 3) as well as in the index AAN patient
(lane 6). Densitometry analysis of the signals relative to
-actin is shown in Figure 3B. Western blot analyses in
the peritoneum of AA-treated rabbits failed to demon-
strate an abnormal expression of collagen III and bFGF
(data not shown).
Detection of specific AA-DNA adducts
AA-DNA adducts were identified in renal and perito-
neal tissue samples from rabbits exposed to high-dose
AA, whereas no such DNA adducts were detected in
controls (Fig. 4) (Table 3). The pattern obtained in rabbit
tissues (Fig. 4 A and B) showed the typical DNA adduct
profile for AA exposure consisting of 7-(deoxyadenosine-
N6-yl)aristolactam I (dA-AAI, spot 1), 7-(deoxyguano-
sine-N6-yl)aristolactam I (dG-AAI, spot 2), and 7-(deoxy-
adenosine-N6-yl)aristolactam II (dA-AAII, spot 3) [9, 20].
These purine DNA adducts are identical to those identi-
fied previously in several organs of rodents treated with
AA [20] as well as in kidney and ureter tissue of patients
with AAN [5, 7, 8, 14]. Quantitative analysis shown in
Table 4 revealed that total DNA binding in rabbit kidney
tissue was approximately 10-fold higher than that in rab-
bit peritoneum tissue.
The adenosine adduct of aristolochic acid I (AAI),
7-(deoxyadenosine-N6-yl)-aristolactam I (dA-AAI, spot
1), the major DNA adduct reported in the Belgian AAN
cohort [5, 7, 8] and other AAN patients [14], was identi-
fied in kidney tissue of the index AAN patient (Fig. 4D).
The mean DNA adduct level ( SD) in the kidney tissue
was 0.42  0.11 per 107 normal nucleotides. In contrast,
no AA-DNA adducts were detected in the peritoneal
tissue sample from the same patient (Fig. 4C). The latter
mononuclear inflammatory cells and few areas of fibrosis (). These
nodules are covered by hyperplastic mesothelial cells (inset) (hematoxy-
lin-eosin original magnification 40).
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Fig. 3. Expression of fibrosis and endothelial markers in the perito-
neum of aristolochic acid nephropathy (AAN) patients, in comparison
with regular peritoneal dialysis patients and healthy controls. (A ) Rep-
resentative immunoblots for collagen III (coll III), basic fibroblast
growth factor (bFGF), endothelial nitric oxide synthase (eNOS), aquap-
orin-1 (AQP1), and -actin in samples from human peritoneum (lanes
1 to 8). Lanes 1, 2, and 3 are samples from peritoneal dialysis patients
with high-average (HA) transport peritoneal membrane (corresponding
to peritoneal dialysis 1, peritoneal dialysis 2, and peritoneal dialysis 3
in Table 2). Lane 4 is a biopsy sample from a peritoneal dialysis patient
with low-average (LA) transport peritoneal membrane (peritoneal dial-
ysis 4 in Table 2). Lane 5 is a biopsy sample from the AAN patient on
hemodialysis (HD) (Case 3 in Table 1), whereas lane 6 is the index
(IC) AAN patient. Lanes 7 and 8 are biopsy samples from healthy
control subjects (Ctls). Peritoneal fibrosis (PF) is a biopsy sample from
a long-term peritoneal dialysis patient with peritoneal fibrosis taken as
a positive control for fibrosis markers. Thirty micrograms of total protein
extract was loaded in each lane. The signal for -actin was obtained in
two different exposures in lanes 1 to 3 and 4 to 8, respectively. (B )
Optical densities (relative to -actin) of the immunoblots for collagen
III, bFGF, eNOS, and AQP1. The lanes correspond to those showed
in (A).
observation was confirmed by the analysis of two addi-
tional peritoneal biopsies from AAN patients, which also
failed to reveal the presence of AA-DNA adducts (data
not shown).
DISCUSSION
One of the most typical histologic features of AAN
is an extensive and hypocellular interstitial renal fibrosis
decreasing in severity from the outer to the inner cortex
[2, 3]. Although the fibrotic process has been docu-
mented in extrarenal tissues [21], the putative involve-
ment of the peritoneum as well as the efficacy of perito-
neal dialysis in patients that have been exposed to AA
remain uncertain. The issue is critical for the choice of
a dialysis modality in AAN patients, who rapidly prog-
ress to end-stage renal failure [11]. Indeed, fibrosis of
the peritoneal membrane, such as observed for instance
in encapsuling peritoneal sclerosis, is associated with hy-
popermeability and dialysis failure [22].
Our detailed analysis of an AAN patient on peritoneal
dialysis for 10 months showed two successive, similar
PET compatible with low-average transport across the
peritoneal membrane. Analysis of the peritoneal biopsy
performed in this patient prior to peritoneal dialysis initi-
ation showed a normal structure of the peritoneal mem-
brane, without areas of fibrosis or vascular proliferation.
Similar findings were obtained in peritoneal biopsies ob-
tained at various stages of renal replacement therapy in
four other patients with documented AAN and renal
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Fig. 4. Autoradiograms of DNA adducts in kidney and peritoneal sam-
ples of aristolochic acid (AA)-exposed rabbits (A and B ) and the
aristolochic acid nephropathy (AAN) index patient (C and D ). DNA-
adduct profiles found in rabbit peritoneum (A) and rabbit kidney tissue
(B) treated intraperitoneally with 0.1 mg/kg AA (5 days/week for 21
months). DNA-adduct profiles found in peritoneum (C) and kidney
tissue (D) of the index AAN patient. dA-AAI (spot 1), 7-(deoxyadeno-
sine-N6-yl)aristolactam I; dG-AAI (spot 2), 7-(deoxyguanosine-N6-yl)-
aristolactam I; and dA-AAII (spot 3), 7-(deoxyadenosine-N6-yl)aristo-
lactam II.
failure (Table 1). The lack of fibrotic changes and neovas-
cularization in the peritoneal membrane was confirmed
by histologic and molecular studies of the peritoneal
tissue of rabbits exposed to a high-dose of AA.
Immunoblotting analyses were performed to evaluate
the expression of important molecular components [23]
in the peritoneal membrane of AAN patients versus
controls and regular peritoneal dialysis patients. Our
results clearly show that collagen III, a marker of fibrosis,
and bFGF, a growth factor involved both in fibrosis and
angiogenesis, are not up-regulated in the peritoneum of
AAN patients and rabbits exposed to high-dose AA.
Since the development of peritoneal fibrosis is associated
with vascular proliferation in the peritoneal membrane
in long-term peritoneal dialysis patients [24], we also
compared the expression of endothelial markers in the
peritoneum of the index AAN patient versus regular
peritoneal dialysis patients and control subjects (Fig. 3).
Our results show that eNOS, which is a functional marker
of the capillary endothelium, was up-regulated in all
peritoneal dialysis patients, and particularly in the high-
average tranporters. In these patients, expression of
bFGF and collagen III was also higher. Thus, our results
confirm that high peritoneal membrane permeability is
associated with an increased endothelial area in the peri-
toneum [25] and that vascular changes observed with
time on peritoneal dialysis might induce submesothelial
fibrosis.
It should be noted that the expression of AQP1 is
relatively increased in the peritoneal tissue of the index
case. The water channel AQP1 is the ultrasmall pore
involved in free-water permeability across the capillary
endothelium. The expression of AQP1 as assessed by
immunoblot may not reflect the amount of permeable
pores [15, 26], and the latter parameter is better assessed
by the sodium sieving. The sodium sieving was indeed
higher in the index case than in regular peritoneal dialysis
patients (Table 2). The reason for the high expression
of AQP1 in the index AAN patient remains to be investi-
gated. Recent studies have demonstrated that the expres-
sion of AQP1 in the capillary endothelium can be regu-
lated at the transcriptional level, and reflected by
modifications of ultrafiltration and sodium sieving [27].
The identification of AA in Chinese herbal medicine
samples [28] and detection of premutagenic AA-DNA
adducts in kidney samples from AAN patients [5, 8, 9]
suggest that AA is directly involved in the development
of renal interstitial fibrosis as well as urothelial atypia
observed in these patients. This hypothesis has been
supported by animal studies in which direct injections
of AA have led to the development of typical renal
interstitial fibrotic lesions and atypia in the upper urinary
tract [10, 29]. The mechanism by which AA induces renal
fibrosis is poorly understood. The AA might have a direct
cytotoxic effect, inducing renal tubular lesions and subse-
quent acellular interstitial fibrosis. Alternatively, AA-
DNA adducts could induce mutations responsible not
only for the development of AAN-associated malignan-
cies [7] but also for the destructive fibrotic process [10].
One could speculate that the absence of AA-DNA ad-
ducts in the peritoneum of patients with AAN is some-
how related to the lack of fibrosis and atypia in this tissue.
Indeed, taking into account the fact that the mesothelium
was not completely preserved, peritoneal samples of AAN
patients did not show cellular atypia. The 32P-postlabeling
analysis on DNA extracted from the peritoneal biopsy of
the index AAN patient and two other AAN patients did
not detect AA-DNA adducts, in contrast with the kidney
(Fig. 4D). The absence of AA-DNA adducts in the hu-
man peritoneal membrane may be explained by local
factors, such as cellular composition or turnover, or, al-
ternatively, the low activity of enzymes involved in the
bioactivation of AA.
Specific AA-DNA adducts were identified in the peri-
toneum of AA-treated rabbits, and, in contrast with the
absence of peritoneal fibrosis, a malignant invasive meso-
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Table 3. AA-DNA adducts in rabbits exposed to high-dose AA and controls
DNA adduct level (meanSD) per 107 normal nucleotides
dA-AAI (Spot 1) dG-AAI (Spot 2) dA-AAII (Spot 3) Total
AA rabbits
Peritoneum (N  6) 2.81.1 2.10.55 5.31.3 10.22.6
Kidney (N  3) 64.719.6 20.77.5 37.012.5 122.438.8
Control rabbits
Peritoneum (N  3) ND ND ND ND
Kidney (N  4) ND ND ND ND
Abbreviations are: AA, aristolochic acid; AA rabbits, AA-exposed rabbits (0.1 mg/kg); dA-AAI, 7-(deoxyadenosine-N6-yl) aristolactam I; dG-AAI, 7-(deoxyguanos-
ine-N6-yl) aristolactam I; dA-AAII, 7-(deoxyadenosine-N6-yl) aristolactam II; ND, not detected.
thelioma was detected in one of the six exposed animals.
These findings may suggest a causal link between AA
exposure, formation of mutagenic AA-DNA adducts,
and the potential development of peritoneal mesotheli-
oma. However, the development of a peritoneal malig-
nancy in this rabbit model could be a consequence of
the direct intraperitoneal administration and/or the high
cumulative dose of AA administrated, resulting from a
higher daily dose (0.1 mg/kg/day) (i.e., at least fourfold
higher than in AAN patients) and a more prolonged
duration of administration (a mean of 21 months in rab-
bits versus 13 months in humans) [29]. Although the
possibility of a link with AA exposure can not be ruled
out, the benign focal nodules observed in another rabbit
most probably represent a nonspecific reaction similar to
that observed in serosal membranes exposed to chronic,
irritative stimuli [30].
CONCLUSION
Our data show that the peritoneum of patients with
AAN does not undergo structural or molecular changes.
Although these observations originate from the few peri-
toneal biopsies available, all patients showed typical
AAN with respect to kidney and urothelial disease.
Based on those observations, peritoneal dialysis should
not be discouraged in these patients. Nevertheless, stud-
ies in a rabbit model of high-dose AA exposure may
suggest a potential risk of peritoneal malignancy.
These results are important since AAN is far from
being limited to an outbreak in Belgium [6, 7] and herbal
medicine has become an increasingly common form of
alternative therapy worldwide [31]. Morevoer, this study
gives insights into molecular mechanisms involved in
structural changes of the peritoneal membrane, including
carcinogenesis, fibrosis, and angiogenesis, and illustrates
that understanding the structure and function of the peri-
toneal membrane can help in addressing clinical prob-
lems.
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